StreetInsider.com News Articles

Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Thu, 28 May 2026 16:05:00 -0400

WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that Ron Renaud, President and Chief Executive Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, at 10:30 am EDT.

A live webcast will be available on the Events page of Kailera’s investor website. A replay of the conference webcast will be archived on the company's website for 90 days.

About Kailera Therapeutics

Kailera Therapeutics

Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Thu, 28 May 2026 16:05:00 -0400

A live webcast will be available on the Events page of Kailera’s investor website. A replay of the conference webcast will be archived on the company's website for 90 days.

About Kailera Therapeutics

Kailera Therapeutics

Form 10-Q Kailera Therapeutics, For: Mar 31

Tue, 26 May 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260526/26550519.html

Form 8-K Kailera Therapeutics, For: May 26

Tue, 26 May 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260526/26550299.html

Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates

Tue, 26 May 2026 16:02:00 -0400

Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline
Initiated five late-stage global clinical trials in obesity, including the ribupatide injection KaiNETIC Phase 3 program
Reported positive topline clinical data from three trials conducted by our partner Hengrui in China, including new topline data from Phase 3 trial of oral small molecule GLP-1 receptor agonist HRS-7535 (KAI-7535) in type 2 diabetes, and first-in-human topline data from Phase 1 trial for injectable tri-agonist HRS-4729 (KAI-4729)
Cash on hand, including IPO proceeds, is expected to fund operations into mid-2028

WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE)

Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates

Tue, 26 May 2026 16:02:00 -0400

Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline
Initiated five late-stage global clinical trials in obesity, including the ribupatide injection KaiNETIC Phase 3 program
Reported positive topline clinical data from three trials conducted by our partner Hengrui in China, including new topline data from Phase 3 trial of oral small molecule GLP-1 receptor agonist HRS-7535 (KAI-7535) in type 2 diabetes, and first-in-human topline data from Phase 1 trial for injectable tri-agonist HRS-4729 (KAI-4729)
Cash on hand, including IPO proceeds, is expected to fund operations into mid-2028

WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE)

Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions